FDA Put Brakes On Penny Stock Kezar Life Sciences' Mid-Stage Study For Lead Development Candidate After Patient Deaths
Portfolio Pulse from Vandana Singh
The FDA has placed a clinical hold on Kezar Life Sciences' mid-stage study of zetomipzomib for lupus nephritis following patient deaths. The company had already suspended the trial based on safety concerns. Kezar's other trials remain unaffected.
October 07, 2024 | 12:50 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Kezar Life Sciences' study for zetomipzomib in lupus nephritis is on hold due to patient deaths, impacting its stock negatively. Other trials continue unaffected.
The FDA's clinical hold on Kezar's key drug trial due to safety concerns is a significant setback, likely leading to negative investor sentiment and a drop in stock price. The company's focus on reallocating resources to other trials may not offset the immediate impact.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100